Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada.
Institute of Pulmonary Medicine, Sackler Faculty of Medicine, Sheba Medical Center, Tel-Aviv University, Tel Aviv, Israel.
Transpl Int. 2021 Dec;34(12):2620-2632. doi: 10.1111/tri.14157. Epub 2021 Nov 16.
Definitions for chronic lung allograft dysfunction (CLAD) phenotypes were recently revised (2019 ISHLT consensus). Post-CLAD onset phenotype transition may occur as a result of change in obstruction, restriction, or RAS-like opacities (RLO). We aimed to assess the prevalence and prognostic implications of these transitions. This was a single-center, retrospective cohort study of bilateral lung transplants performed in 2009-2015. CLAD phenotypes were determined per ISHLT guidelines. CLAD phenotype transition was defined as a sustained change in obstruction, restriction or RLO. We specifically focused on phenotype changes based on RLO emergence. Association of RLO development with time to death or retransplant were assessed using Kaplan-Meier and Cox proportional hazards models. Among 211 patients with CLAD, 47 (22.2%) experienced a phenotype transition. Nineteen patients developed RLO. Development of RLO phenotype after CLAD onset was associated with a shorter time to death/retransplant when considering the entire CLAD patient cohort (HR = 4.00, CI 2.74-5.83, P < 0.001) and also when restricting the analysis to only patients with a Non-RLO phenotype at CLAD onset (HR 9.64, CI 5.52-16.84, P < 0.0001). CLAD phenotype change based on emergence of RAS-like opacities implies a worse outcome. This highlights the clinical importance of imaging follow-up to monitor for phenotype transitions after CLAD onset.
慢性肺移植物功能障碍(CLAD)表型的定义最近进行了修订(2019 年 ISHLT 共识)。CLAD 发病后的表型转变可能是由于阻塞、限制或 RAS 样混浊(RLO)的变化引起的。我们旨在评估这些转变的流行率和预后意义。这是一项在 2009 年至 2015 年期间进行的双侧肺移植的单中心回顾性队列研究。根据 ISHLT 指南确定 CLAD 表型。CLAD 表型转变定义为阻塞、限制或 RLO 的持续变化。我们特别关注基于 RLO 出现的表型变化。使用 Kaplan-Meier 和 Cox 比例风险模型评估 RLO 发展与死亡或再移植时间的关系。在 211 例 CLAD 患者中,47 例(22.2%)经历了表型转变。19 例患者出现 RLO。在考虑整个 CLAD 患者队列时,CLAD 发病后出现 RLO 表型与死亡/再移植时间较短相关(HR=4.00,CI 2.74-5.83,P<0.001),并且当将分析仅限于 CLAD 发病时具有非-RLO 表型的患者时,相关性仍然存在(HR 9.64,CI 5.52-16.84,P<0.0001)。基于 RAS 样混浊出现的 CLAD 表型变化意味着预后更差。这突出了在 CLAD 发病后进行影像学随访以监测表型转变的临床重要性。